公开(公告)号：US20210283262A1

公开(公告)日：2021-09-16

申请号：US16323319

申请日：2017-08-04

Applicant: NOVARTIS AG

Inventor： John DOMINY ,  Robert DUNN ,  Scott GLASER ,  Mark KEATING ,  Carla KLATTENHOFF ,  Igor SPLAWSKI

IPC: A61K47/54 ,  C07K16/28 ,  C07K16/22

Abstract: The present disclosure is directed to methods of immunization and methods for generating antibodies using compositions comprising cationic lipids and polynucleotide molecules, such as polyribonucleotide molecules, e.g., mRNA, which code for immunogens (e.g., a target protein or a fragment thereof).

公开(公告)号：US20210155713A1

公开(公告)日：2021-05-27

申请号：US17058870

申请日：2019-05-29

Applicant: Novartis AG

Inventor： Michael DIDONATO ,  Christoph ERKEL ,  Anna Galkin ,  Scott GLASER ,  Klaus Felix HARTLEPP ,  Yong JIA ,  Alexandra KRAUS ,  Christian Cho-Hua LEE ,  Sarah Michelle RUE ,  Jian SHI ,  Xenia Karola WEZLER

IPC: C07K16/40 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.